Dupilumab 300 mg injection contains the active ingredient Dupilumab, a fully human monoclonal antibody used for the treatment of various chronic inflammatory conditions driven by type 2 inflammation.

It is primarily indicated in diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, where overactivation of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways plays a key role.

Dupilumab works by inhibiting IL-4 and IL-13 signaling, thereby reducing inflammation, improving symptoms, and preventing disease progression.

• Moderate-to-severe atopic dermatitis
• Moderate-to-severe asthma (as an add-on maintenance therapy)
• Chronic rhinosinusitis with nasal polyposis
• Eosinophilic esophagitis (in certain patient populations)

This therapy helps improve symptoms, reduce exacerbations, and enhance quality of life.

Dupilumab acts as an interleukin-4 receptor alpha antagonist.

It works by:

• Blocking IL-4 and IL-13 signaling pathways
• Reducing type 2 inflammation
• Decreasing itching, skin lesions, and airway inflammation
• Lowering frequency of asthma exacerbations

Clinical studies have shown significant improvement in skin clearance, lung function, and overall disease control.

• Administered as a subcutaneous injection.
• Initial loading dose followed by maintenance dosing as prescribed.
• Usually given every 2 weeks depending on indication.
• Injection should be administered into the thigh, abdomen, or upper arm.
• Should be used under medical supervision.

Common side effects include:

• Injection site reactions
• Conjunctivitis (eye inflammation)
• Blepharitis
• Oral herpes
• Eosinophilia

Most side effects are mild to moderate and manageable.

Patients should inform their healthcare provider about all medications they are taking.

Dupilumab may interact with:

Live vaccines (should be avoided during treatment).

Immunosuppressive therapies.

No major cytochrome P450-mediated drug interactions are expected, but caution is advised.

• Store in a refrigerator at 2°C–8°C
• Do not freeze.
• Keep in original packaging to protect from light.
• Allow it to reach room temperature before administration (do not heat artificially).
• Keep out of reach of children.

• Adhere strictly to the prescribed dosing schedule.
• Regular follow-up is recommended to monitor response.
• Avoid live vaccines during treatment.
• Report any eye-related symptoms promptly.
• Do not discontinue treatment without consulting your doctor.